AA
ADMS

ALPS Advisors’s Adamas Pharmaceuticals ADMS Stock Holding History

ALPS Advisors’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-66,026
Closed -$469K – 905
2019
Q1 		$469K Buy
66,026
+2,860
+5% +$25.7K ﹤0.01% 540
2018
Q4 		$539K Buy
63,166
+15,050
+31% +$196K ﹤0.01% 457
2018
Q3 		$963K Buy
48,116
+8,965
+23% +$211K 0.01% 418
2018
Q2 		$1.01M Buy
39,151
+4,057
+12% +$112K 0.01% 335
2018
Q1 		$839K Buy
35,094
+9,853
+39% +$311K 0.01% 347
2017
Q4 		$855K Buy
25,241
+3,069
+14% +$85.7K 0.01% 288
2017
Q3 		$469K Buy
22,172
+1,990
+10% +$36.5K ﹤0.01% 630
2017
Q2 		$353K Buy
20,182
+1,272
+7% +$21K ﹤0.01% 703
2017
Q1 		$331K Sell
18,910
-2,215
-10% -$37.7K ﹤0.01% 680
2016
Q4 		$357K Sell
21,125
-6,831
-24% -$106K ﹤0.01% 645
2016
Q3 		$459K Sell
27,956
-2,426
-8% -$36.9K ﹤0.01% 316
2016
Q2 		$460K Buy
30,382
+6,296
+26% +$104K ﹤0.01% 315
2016
Q1 		$348K Sell
24,086
-182
-0.7% -$3.06K ﹤0.01% 573
2015
Q4 		$687K Sell
24,268
-3,628
-13% -$61.1K 0.01% 242
2015
Q3 		$4.67K Buy
27,896
+10,211
+58% +$232K ﹤0.01% 526
2015
Q2 		$464K Buy
+17,685
New +$344K ﹤0.01% 581

Other funds holding ADMS

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

ALPS Advisors's ADMS Position: Q2 2019 in Review

ALPS Advisors sold out of Adamas Pharmaceuticals (ADMS) in Q2 2019, closing a stake of 66,026 shares — an estimated $469K sold.

ALPS Advisors first reported a position in ADMS in Q2 2015 and held it in 16 quarters. The position peaked at $1.01M in Q2 2018. 78 funds tracked by Wall St. Rank hold ADMS as of Q2 2019.

  • ALPS Advisors reported no remaining Adamas Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • ALPS Advisors sold 66,026 Adamas Pharmaceuticals shares in Q2 2019, an estimated $469K.
  • ALPS Advisors first reported a position in Adamas Pharmaceuticals in Q2 2015 and held it in 16 quarters.
  • ALPS Advisors's Adamas Pharmaceuticals position peaked at $1.01M in Q2 2018.
  • 78 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q2 2019.

Based on ALPS Advisors's 13F filing for Q2 2019, filed 7 Aug 2019.